{
  "id": 16902331,
  "title": "Why An AI Biotech Startup Launched A $600 Million Fund To Buy Stalled Drugs",
  "url": "https://urgent.news/2026/10/28/why-an-ai-biotech-startup-launched-a-600-million-fund-to-buy-stalled",
  "topic": "ai",
  "section": "AI",
  "published": "2026-10-28T13:00:00.000Z",
  "source": {
    "name": "Forbes",
    "slug": "forbes",
    "url": "https://www.forbes.com/sites/innovationrx/2026/10/28/why-an-ai-biotech-startup-launched-a-600-million-fund-to-buy-stalled-drugs/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Most AI drug development firms are focused on discovery. AI biotech Formation Bio is betting the real bottleneck is clinical trials. With a new $600 million fund to buy or license potential drugs that have stalled out, the startup now hopes to prove that it’s right.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}